Roche's Pharma Research & Early Development (pRED) organization is managing the Phase I and Phase II development of 23 new molecular entities (NMEs), while the company's Pharma organization is managing the Phase II/III to Phase III development of four compounds that originated in pRED. Phase II and Phase III compounds listed below. The full list, including Phase I compounds, is available online